Top

12-03-2025 | Diabetic Retinopathy | Article

MAP4K4 aggravates microvascular anomalies in diabetic retinopathy in a YTHDF2-dependent manner

Authors: Qian Yang, Pei-wen Zhu, Yan-jun Wen, Ran Zhang, Wen-wen Chen, Xin Huang, Qing Chang

Abstract

Aims/hypothesis

Signalling pathways that regulate endothelial cell (EC) dysfunction, ischaemia and inflammation play a crucial role in retinal microangiopathy such as diabetic retinopathy. MAP4K4 is highly expressed in ECs. However, the involvement of MAP4K4 in retinal vasculopathy of diabetic retinopathy remains unclear.

Methods

We analysed publicly available single-cell RNA sequencing (scRNA-seq) data from fibrovascular membranes (FVMs) from eight individuals with proliferative diabetic retinopathy (PDR) and normal retinas from 11 individuals without diabetes. Using db/db mice and human primary retinal endothelial cells (HRMECs), we further investigated the effects of MAP4K4 on retinal microangiopathy and endothelial dysfunction to explore the underlying regulatory mechanisms.

Results

The scRNA-seq analysis revealed that MAP4K4 was predominantly expressed in retinal ECs, with elevated expression in FVMs from individuals with PDR compared with normal retinas from individuals without diabetes. This finding was confirmed at the protein level, with MAP4K4 expression and activity being upregulated in both the FVMs of individuals with PDR and the retinas of db/db mice. Inhibition of MAP4K4 using DMX-5804 alleviated retinal microvascular leakage by enhancing the expression and integrity of junctional proteins in both ECs from db/db mice and HRMECs. Additionally, DMX-5804 reduced retinal angiogenesis by inhibiting EC migration and vascular sprouting. Mechanistically, MAP4K4 regulated EC characteristics through NF-κB signalling pathway activity. The exacerbating effect of recombinant MAP4K4 on diabetic retinopathy in db/db mice was mitigated by a p65 inhibitor, confirming the involvement of NF-κB. Moreover, MAP4K4 expression was regulated by YTH N⁶-methyladenosine RNA-binding protein 2 (YTHDF2), which modulates the stability of MAP4K4 mRNA.

Conclusions/interpretation

Our study highlights the critical role of MAP4K4 in EC dysfunction and diabetic retinal microangiopathy, providing new insights into its molecular pathogenesis. Targeting MAP4K4, particularly through modulation of the YTHDF2/MAP4K4/NF-κB axis, may provide a novel therapeutic strategy for diabetic retinopathy.

Graphical Abstract

Available only for authorised users

Levine SR, Sapieha P, Dutta S, Sun JK, Gardner TW (2022) It is time for a moonshot to find ‘cures’ for diabetic retinal disease. Prog Retin Eye Res 90:101051. https://doi.org/10.1016/j.preteyeres.2022.101051CrossRefPubMed

Daruich A, Matet A, Moulin A et al (2018) Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res 63:20–68. https://doi.org/10.1016/j.preteyeres.2017.10.006CrossRefPubMed

Antonetti DA, Silva PS, Stitt AW (2021) Current understanding of the molecular and cellular pathology of diabetic retinopathy. Nat Rev Endocrinol 17(4):195–206. https://doi.org/10.1038/s41574-020-00451-4CrossRefPubMedPubMedCentral

Tang L, Xu GT, Zhang JF (2023) Inflammation in diabetic retinopathy: possible roles in pathogenesis and potential implications for therapy. Neural Regen Res 18(5):976–982. https://doi.org/10.4103/1673-5374.355743CrossRefPubMed

Yang J, Liu Z (2022) Mechanistic pathogenesis of endothelial dysfunction in diabetic nephropathy and retinopathy. Front Endocrinol (Lausanne) 13:816400. https://doi.org/10.3389/fendo.2022.816400CrossRefPubMed

Zhang J, Zhang J, Zhang C et al (2022) Diabetic macular edema: current understanding, molecular mechanisms and therapeutic implications. Cells 11(21):3362. https://doi.org/10.3390/cells11213362CrossRefPubMedPubMedCentral

Arima M, Nakao S, Yamaguchi M et al (2020) Claudin-5 redistribution induced by inflammation leads to anti-VEGF-resistant diabetic macular edema. Diabetes 69(5):981–999. https://doi.org/10.2337/db19-1121CrossRefPubMed

Lange C, Storkebaum E, de Almodovar CR, Dewerchin M, Carmeliet P (2016) Vascular endothelial growth factor: a neurovascular target in neurological diseases. Nat Rev Neurol 12(8):439–454. https://doi.org/10.1038/nrneurol.2016.88CrossRefPubMed

Hartnett ME (2020) Retinopathy of prematurity: evolving treatment with anti-vascular endothelial growth factor. Am J Ophthalmol 218:208–213. https://doi.org/10.1016/j.ajo.2020.05.025CrossRefPubMedPubMedCentral

10.

Delpire E (2009) The mammalian family of sterile 20p-like protein kinases. Pflugers Arch 458(5):953–967. https://doi.org/10.1007/s00424-009-0674-yCrossRefPubMed

11.

Wright JH, Wang X, Manning G et al (2003) The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol 23(6):2068–2082. https://doi.org/10.1128/MCB.23.6.2068-2082.2003CrossRefPubMedPubMedCentral

12.

Aouadi M, Tesz GJ, Nicoloro SM et al (2009) Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458(7242):1180–1184. https://doi.org/10.1038/nature07774CrossRefPubMedPubMedCentral

13.

Vitorino P, Yeung S, Crow A et al (2015) MAP4K4 regulates integrin–FERM binding to control endothelial cell motility. Nature 519(7544):425–430. https://doi.org/10.1038/nature14323CrossRefPubMed

14.

Ammirati M, Bagley SW, Bhattacharya SK et al (2015) Discovery of an in vivo tool to establish proof-of-concept for MAP4K4-based antidiabetic treatment. ACS Med Chem Lett 6(11):1128–1133. https://doi.org/10.1021/acsmedchemlett.5b00215CrossRefPubMedPubMedCentral

15.

Meng B, Li Y, Ding Y et al (2021) Myeloid-derived growth factor inhibits inflammation and alleviates endothelial injury and atherosclerosis in mice. Sci Adv 7(21):eabe6903. https://doi.org/10.1126/sciadv.abe6903CrossRefPubMedPubMedCentral

16.

Gao X, Gao C, Liu G, Hu J (2016) MAP4K4: an emerging therapeutic target in cancer. Cell Biosci 6:56. https://doi.org/10.1186/s13578-016-0121-7CrossRefPubMedPubMedCentral

17.

Chen Y, Li S, Guan B et al (2024) MAP4K4 exacerbates cardiac microvascular injury in diabetes by facilitating S-nitrosylation modification of Drp1. Cardiovasc Diabetol 23(1):164. https://doi.org/10.1186/s12933-024-02254-7CrossRefPubMedPubMedCentral

18.

Zou Z, Dong YS, Liu DD et al (2021) MAP4K4 induces early blood–brain barrier damage in a murine subarachnoid hemorrhage model. Neural Regen Res 16(2):325–332. https://doi.org/10.4103/1673-5374.290904CrossRefPubMed

19.

Pannekoek WJ, Linnemann JR, Brouwer PM, Bos JL, Rehmann H (2013) Rap1 and Rap2 antagonistically control endothelial barrier resistance. PLoS One 8(2):e57903. https://doi.org/10.1371/journal.pone.0057903CrossRefPubMedPubMedCentral

20.

Butler A, Hoffman P, Smibert P, Papalexi E, Satija R (2018) Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 36(5):411–420. https://doi.org/10.1038/nbt.4096CrossRefPubMedPubMedCentral

21.

Korsunsky I, Millard N, Fan J et al (2019) Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods 16(12):1289–1296. https://doi.org/10.1038/s41592-019-0619-0CrossRefPubMedPubMedCentral

22.

Niu C, Chen Z, Kim KT et al (2019) Metformin alleviates hyperglycemia-induced endothelial impairment by downregulating autophagy via the Hedgehog pathway. Autophagy 15(5):843–870. https://doi.org/10.1080/15548627.2019.1569913CrossRefPubMedPubMedCentral

23.

Enright JM, Zhang S, Thebeau C et al (2020) Fenofibrate reduces the severity of neuroretinopathy in a type 2 model of diabetes without inducing peroxisome proliferator-activated receptor alpha-dependent retinal gene expression. J Clin Med 10(1):126. https://doi.org/10.3390/jcm10010126CrossRefPubMedPubMedCentral

24.

Chen W, Zhang J, Zhang P et al (2019) Role of TLR4–MAP4K4 signaling pathway in models of oxygen-induced retinopathy. FASEB J 33(3):3451–3464. https://doi.org/10.1096/fj.201801086RRCrossRefPubMed

25.

Tomita Y, Shao Z, Cakir B, Kotoda Y, Fu Z, Smith LEH (2020) An ex vivo choroid sprouting assay of ocular microvascular angiogenesis. J Vis Exp 162:10.3791/61677. https://doi.org/10.3791/61677CrossRef

26.

Zhu R, Ji X, Wu X et al (2022) Melatonin antagonizes ovarian aging via YTHDF2–MAPK–NF-κB pathway. Genes Dis 9(2):494–509. https://doi.org/10.1016/j.gendis.2020.08.005CrossRefPubMed

27.

Liao YL, Fang YF, Sun JX, Dou GR (2024) Senescent endothelial cells: a potential target for diabetic retinopathy. Angiogenesis 27(4):663–679. https://doi.org/10.1007/s10456-024-09943-7CrossRefPubMedPubMedCentral

28.

Gui F, You Z, Fu S, Wu H, Zhang Y (2020) Endothelial dysfunction in diabetic retinopathy. Front Endocrinol (Lausanne) 11:591. https://doi.org/10.3389/fendo.2020.00591CrossRefPubMed

29.

Jia G, Bai H, Mather B, Hill MA, Jia G, Sowers JR (2024) Diabetic vasculopathy: molecular mechanisms and clinical insights. Int J Mol Sci 25(2):804. https://doi.org/10.3390/ijms25020804CrossRefPubMedPubMedCentral

30.

Joy SS, Siddiqui K (2019) Molecular and pathophysiological mechanisms of diabetic retinopathy in relation to adhesion molecules. Curr Diabetes Rev 15(5):363–371. https://doi.org/10.2174/1573399814666181017103844CrossRefPubMed

31.

Dehdashtian E, Mehrzadi S, Yousefi B et al (2018) Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. Life Sci 193:20–33. https://doi.org/10.1016/j.lfs.2017.12.001CrossRefPubMed

32.

van der Wijk AE, Hughes JM, Klaassen I, Van Noorden CJF, Schlingemann RO (2017) Is leukostasis a crucial step or epiphenomenon in the pathogenesis of diabetic retinopathy? J Leukoc Biol 102(4):993–1001. https://doi.org/10.1189/jlb.3RU0417-139CrossRefPubMed

33.

Drankowska J, Kos M, Kosciuk A et al (2019) MMP targeting in the battle for vision: recent developments and future prospects in the treatment of diabetic retinopathy. Life Sci 229:149–156. https://doi.org/10.1016/j.lfs.2019.05.038CrossRefPubMed

34.

Roth Flach RJ, Skoura A, Matevossian A et al (2015) Endothelial protein kinase MAP4K4 promotes vascular inflammation and atherosclerosis. Nat Commun 6:8995. https://doi.org/10.1038/ncomms9995CrossRefPubMed

35.

Gao X, Chen G, Gao C et al (2017) MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance. Mol Oncol 11(6):628–639. https://doi.org/10.1002/1878-0261.12055CrossRefPubMedPubMedCentral

36.

Yue J, Xie M, Gou X, Lee P, Schneider MD, Wu X (2014) Microtubules regulate focal adhesion dynamics through MAP4K4. Dev Cell 31(5):572–585. https://doi.org/10.1016/j.devcel.2014.10.025CrossRefPubMedPubMedCentral

37.

Crespo-Garcia S, Tsuruda PR, Dejda A et al (2021) Pathological angiogenesis in retinopathy engages cellular senescence and is amenable to therapeutic elimination via BCL-xL inhibition. Cell Metab 33(4):818-832 e817. https://doi.org/10.1016/j.cmet.2021.01.011CrossRefPubMed

38.

Connor KM, Krah NM, Dennison RJ et al (2009) Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc 4(11):1565–1573. https://doi.org/10.1038/nprot.2009.187CrossRefPubMedPubMedCentral

39.

Schwaid AG, Su C, Loos P et al (2015) MAP4K4 is a threonine kinase that phosphorylates FARP1. ACS Chem Biol 10(12):2667–2671. https://doi.org/10.1021/acschembio.5b00679CrossRefPubMed

40.

LeClaire LL, Rana M, Baumgartner M, Barber DL (2015) The Nck-interacting kinase NIK increases Arp2/3 complex activity by phosphorylating the Arp2 subunit. J Cell Biol 208(2):161–170. https://doi.org/10.1083/jcb.201404095CrossRefPubMedPubMedCentral

41.

Osada T, Gu YH, Kanazawa M et al (2011) Interendothelial claudin-5 expression depends on cerebral endothelial cell-matrix adhesion by β₁-integrins. J Cereb Blood Flow Metab 31(10):1972–1985. https://doi.org/10.1038/jcbfm.2011.99CrossRefPubMedPubMedCentral

42.

Welser JV, Halder SK, Kant R, Boroujerdi A, Milner R (2017) Endothelial α6β4 integrin protects during experimental autoimmune encephalomyelitis-induced neuroinflammation by maintaining vascular integrity and tight junction protein expression. J Neuroinflammation 14(1):217. https://doi.org/10.1186/s12974-017-0987-2CrossRefPubMedPubMedCentral

43.

Camillo C, Facchinello N, Villari G et al (2021) LPHN2 inhibits vascular permeability by differential control of endothelial cell adhesion. J Cell Biol 220(11):e202006033. https://doi.org/10.1083/jcb.202006033CrossRefPubMedPubMedCentral

44.

Ross EC, Olivera GC, Barragan A (2019) Dysregulation of focal adhesion kinase upon Toxoplasma gondii infection facilitates parasite translocation across polarised primary brain endothelial cell monolayers. Cell Microbiol 21(9):e13048. https://doi.org/10.1111/cmi.13048CrossRefPubMed

45.

Zhu X, Zhou C, Zhao S, Zheng Z (2023) Role of m6A methylation in retinal diseases. Exp Eye Res 231:109489. https://doi.org/10.1016/j.exer.2023.109489CrossRefPubMed

46.

Chen X, Wang Y, Wang JN et al (2024) Lactylation-driven FTO targets CDK2 to aggravate microvascular anomalies in diabetic retinopathy. EMBO Mol Med 16(2):294–318. https://doi.org/10.1038/s44321-024-00025-1CrossRefPubMedPubMedCentral

Title: MAP4K4 aggravates microvascular anomalies in diabetic retinopathy in a YTHDF2-dependent manner
Authors: Qian Yang
Pei-wen Zhu
Yan-jun Wen
Ran Zhang
Wen-wen Chen
Xin Huang
Qing Chang
Publication date: 12-03-2025
Publisher: Springer Berlin Heidelberg
Keywords: Diabetic Retinopathy
Diabetic Retinopathy
Published in: Diabetologia
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-025-06398-3

Elevate your expertise in aplastic anemia (Link opens in a new window)

Aplastic Anemia
Independent Medical Education

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases.

Supported by:

Pfizer

Developed by: Springer Healthcare IME

Learn more

Keynote series | Spotlight on menopause

Menopause
Video Series

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Prof. Martha Hickey

Dr. Claudia Barth

Dr. Samar El Khoudary

Developed by: Springer Medicine

Watch now